Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 7/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 5/20 | 0.40 |
| ▸ | HTR2B | P41595 | 4/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1858975 | 0.80 | TLR9 (0.45) | FEN1ALOX5APBRD4XDH | |
| SCHEMBL27778769 | 0.77 | ALPL (0.38) | FEN1ALOX5AP | |
| SCHEMBL2091970 | 0.75 | PARP15 (0.39) | BRD4 | |
| SCHEMBL2089607 | 0.75 | KMO (0.54) | BRD4XDH | |
| SCHEMBL2088475 | 0.75 | PDK2 (0.41) | FEN1ALOX5APTRPA1TRPM8TRPV1 | |
| SCHEMBL26770363 | 0.74 | HTR2C (0.47) | HTR2CHTR2BHTR2A | |
| SCHEMBL2090174 | 0.74 | MAPT (0.47) | BRD4XDH | |
| SCHEMBL1854515 | 0.72 | XDH (0.45) | XDH | |
| SCHEMBL24170303 | 0.70 | HTR2C (0.44) | HTR2CHTR2BHTR2A | |
| SCHEMBL26770383 | 0.70 | HTR2A (0.44) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118067-B1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH SPA (IT) | 2013-05-08 | — | — | EP | disclosed |
| US-8163729-B2 | Modulators of α7 nicotinic acetylcholine receptors and therapeutic uses thereof | WYETH (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010009290-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20090264648-A1 | SYNTHESIS OF PYRAZOLES | WYETH (US) | 2009-10-22 | — | — | US | disclosed |
| WO-2009091832-A1 | SYNTHESIS OF PYRAZOLES | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | CHRNA7, CHRNA2, CHRNA6 | FEN1 4816/4885ALOX5AP 1256/4885HTR2C 418/4885 |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | CHRNA7, CHRNA6, CHRNA2 | FEN1 4759/4885ALOX5AP 1990/4885HTR2C 307/4885 |
| US-20090264648-A1 | SYNTHESIS OF PYRAZOLES | CHRNA7, CHRNA5, CHRNA3 | FEN1 4745/4885ALOX5AP 1734/4885HTR2C 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.